18105 SE MILL PLAIN BLVD, VANCOUVER, WA
Reports Business Updates and Second Quarter 2026 Financial and Operating Results
Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Absci Corporation Annual Meeting Results; Directors Elected and Accountant Ra...
Reports Business Updates and First Quarter 2026 Financial and Operating Results
Annual Report to Security Holders
Investor Presentation
Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload